Restless Legs Syndrome Clinical Trial
— Glu-RESTOfficial title:
A Proof of Concept, Multicentre, Phase 2, Double-Blind, Randomized, Placebo-Controlled Study on the Efficacy, Safety and Tolerability of d-Methadone in Moderate to Very Severe Restless Legs Syndrome With Periodic Limb Movements: the Glu-REST Study
Proof of concept, double-blind, randomized, placebo-controlled trial with d-methadone proposed for the first time for use in the treatment of patients diagnosed with primary, moderate to very severe Restless Legs Syndrome (RLS). Its glutamatergic mechanism of action might be effective on RLS arousal pattern and sleep disturbance which highly impair the quality of life of RLS's patients. Patients will take the study drug/placebo once a day for 30 consecutive days.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 30, 2025 |
Est. primary completion date | July 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Diagnosis of primary RLS. - Moderate to very severe RLS defined as IRLS-RS score > 10. - Written informed consent. - Willingness and ability to participate in the trial Exclusion Criteria: - Positive history of known causes of secondary RLS. - Any other concomitant treatment for RLS (wash-out period: at least 7 days). - Moderate-severe sleep apnea defined as Apnea Hypopnea Index = 15. - History or presence of clinically significant abnormality as assessed by neurological examination which in the opinion of the Investigator would jeopardize the safety of the patients or the validity of the study results. - Evidence of clinically significant hepatic or renal impairment - History or family history of sudden unexplained death or long QT syndrome. - Any 12-lead ECG with demonstration of QTc = 450 msec or a QRS interval = 120 msec at Screening. - Concomitant use of psycho-drugs dopamine agonists and opioids (wash-out period: at least 7 days). - History or presence of any condition in which an opioid is contraindicated - History of allergy or hypersensitivity to methadone or related drugs. - Any clinically significant neurological, sleep, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, chronic pain, psychiatric or gastrointestinal disorder. - Women who are pregnant or breast feeding. - Inability to follow the procedures of the study, (e.g. due to language problems, psychological disorders, dementia, etc. of the participant). - Previous enrolment into the current study. - Enrolment of the investigator, his/her family members, employees and other dependent persons. - Participation in another study with investigational drug within the 30 days preceding and during the present study. |
Country | Name | City | State |
---|---|---|---|
Italy | Sleep Center, IRCCS San Raffaele | Milan | |
Switzerland | Schlaf-Wach-Epilepsie Zentrum, Inselspital | Bern | |
Switzerland | Neurologie / Schlaflabor Kantonsspital Graubünden | Chur | |
Switzerland | Sleep Center, Neurocenter of Southern Switzerland | Lugano |
Lead Sponsor | Collaborator |
---|---|
Mauro Manconi | Clinical Trial Unit Ente Ospedaliero Cantonale |
Italy, Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of d-methadone | The percentage of responders to d-methadone treatment. A responder is defined as patient who has = 50% reduction in the International RLS Rating Scale (IRLS-RS) score from baseline to end of the 30-day treatment period. | 30 days | |
Secondary | Insomnia severity | Change in insomnia severity from baseline to the end of 10-day dosing period and to end of the treatment period assessed by a using the Insomnia Severity Index (ISI) | 10 and 30 days | |
Secondary | Change in Quality of life | Change in quality of life from baseline to the end of 10-day dosing period and to end of the treatment period assessed assessed by a using the Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL) | 10 and 30 days | |
Secondary | Periodic limb movements of sleep index | Change in Periodic limb movements of sleep (PLMS) index from baseline to end of 10-day dosing period measured by means of polysomnography recording | 10 days | |
Secondary | Actigrafic parameters | Change from baseline to the end of 10-day dosing period and to end of the treatment period on Total Sleep Time, Sleep Latency and Sleep Efficacy acquired assessed by actigraphy with measurements performed one week prior to the start of treatment, during the 10-day dosing period and one week at the end of the treatment. | 10 and 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04786314 -
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome
|
N/A | |
Completed |
NCT01455012 -
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
|
Phase 4 | |
Terminated |
NCT01192503 -
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT00721279 -
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
|
N/A | |
Completed |
NCT00530530 -
ASP8825 - Study in Patients With Restless Legs Syndrome
|
Phase 2 | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00375284 -
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
|
Phase 4 | |
Completed |
NCT00479531 -
Sequential Compression Devices for Treatment of Restless Legs Syndrome
|
Phase 3 | |
Recruiting |
NCT05581576 -
Pitolisant in Refractory Restless Legs Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03218969 -
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
|
Phase 1/Phase 2 | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT05787080 -
Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)
|
N/A | |
Not yet recruiting |
NCT05529095 -
Sublingual Apomorphine in Refractory Restless Legs Syndrome
|
Phase 4 | |
Recruiting |
NCT05044520 -
Clinical Features Associated With Restless Legs Syndrome.
|
||
Withdrawn |
NCT03849001 -
Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS
|
N/A | |
Completed |
NCT03076541 -
Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.
|
N/A | |
Completed |
NCT02532608 -
Infra-slow Oscillations During Sleep
|
N/A | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT00748098 -
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
|
Phase 3 | |
Completed |
NCT00373542 -
12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
|
Phase 4 |